Jupiter Neurosciences, Inc. (NASDAQ:JUNS – Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 938,810 shares, a growth of 453.3% from the June 15th total of 169,677 shares. Currently, 4.2% of the company’s shares are sold short. Based on an average daily trading volume, of 5,496,954 shares, the days-to-cover ratio is currently 0.2 days.
Institutional Investors Weigh In On Jupiter Neurosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of Jupiter Neurosciences by 27.8% in the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Allen Capital Group LLC purchased a new stake in shares of Jupiter Neurosciences during the 4th quarter worth about $31,000. Yorkville Advisors Global LP purchased a new stake in shares of Jupiter Neurosciences during the 4th quarter worth about $135,000. Finally, Vestor Capital LLC grew its holdings in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.
Jupiter Neurosciences Stock Down 3.1%
Shares of NASDAQ JUNS traded down $0.01 during trading on Friday, hitting $0.19. 641,407 shares of the company traded hands, compared to its average volume of 3,405,302. Jupiter Neurosciences has a 1 year low of $0.17 and a 1 year high of $3.33. The company has a 50-day moving average price of $0.26 and a 200-day moving average price of $0.49. The firm has a market capitalization of $6.89 million, a P/E ratio of -0.70 and a beta of 1.73.
Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.23 million.
Jupiter Neurosciences Company Profile
Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.
Featured Stories
- Five stocks we like better than Jupiter Neurosciences
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
